Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Paolieri F"" wg kryterium: Autor


Tytuł :
88PRole of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group.
Autorzy :
Re, M Del
Crucitta, S
Sbrana, A
Rofi, E
Paolieri, F
Galli, L
Falcone, A
Schaik, R van
Jenster, G
Morganti, R
Pokaż więcej
Temat :
HORMONE therapy
EXPERIMENTAL medicine
SURGICAL technology
ACTORS
Źródło :
Annals of Oncology; 2018 Supplement, Vol. 29, pN.PAG-N.PAG, 1p
Czasopismo naukowe
Tytuł :
Follicular thyroid cells of autoimmune thyroiditis may coexpress ICAM-1 (CD54) and its natural ligand LFA-1 (CD11a/CD18)
Autorzy :
MD
5710, no.
Support in part by Consiglio Nazionale delle Ricerche P.F. Fattori di Mallatia SP2 grant to G.W. Can, Consiglio Nazionale delle Ricerche P.F. ''Ingegneria genetica'' grant no. 91.00018 to
Bagnasco, M.
Pesce, G.P.
Caretto, A.
Paolieri, F.
Pronzato, C.
Villaggio, B.
Giordano, C.
Betterle, C.
Canonica, G.W.
Pokaż więcej
Źródło :
The Journal of Allergy and Clinical Immunology; May 1995, Vol. 95 Issue: 5 p1036-1043, 8p
Periodyk
Tytuł :
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Autorzy :
Rebuzzi SE; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino of Genova, Largo Rosanna Benzi 10, Genova, 16132, Italy.
Signori A; Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy.
Banna GL; Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK Cannizzaro Hospital, Catania, Italy.
Maruzzo M; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.
De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Pedrazzoli P; Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.
Sbrana A; Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Zucali PA; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy.
Masini C; Medical Oncology Unit, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Naglieri E; Division of Medical Oncology, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Procopio G; SS Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Merler S; Department of Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona,Verona, Italy.
Tomasello L; Academic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy.
Fratino L; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano CRO-IRCCS, Aviano, Italy.
Baldessari C; Medical Oncology Unit, Department of Oncology and Hemathology, University Hospital of Modena, Modena, Italy.
Ricotta R; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Panni S; Medical Oncology Unit, ASST - Istituti Ospitalieri Cremona Hospital, Cremona, Italy.
Mollica V; Oncologia Medica, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy.
Sorarù M; U.O. Oncologia, Ospedale di Camposampiero, Italy.
Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy.
Cortellini A; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Prati V; Medical Oncology Unit, ASL CN 2, Alba-Bra, Italy.
Soto Parra HJ; Department of Oncology, Medical Oncology, University Hospital Policlinico-San Marco, Catania, Italy.
Stellato M; Department of Medical Oncology, Università Campus Bio-Medico of Roma, Rome, Italy.
Atzori F; Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy.
Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
Messina C; Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.
Messina M; UOC Oncologia Medica, Istituto Fondazione G. Giglio, Cefalù, Italy.
Morelli F; Medical Oncology Department, Casa Sollievo Della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.
Prati G; Department of oncology and advanced technologies AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy.
Nolè F; Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milano, Italy.
Vignani F; Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy.
Cavo A; Oncology Unit, Villa Scassi Hospital, Genova, Italy.
Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, Italy.
Pierantoni F; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.
Casadei C; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Chiellino S; Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.
Paolieri F; Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Perrino M; Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Rozzano, Milano, Italy.
Brunelli M; Department of Diagnostics and Public Health, Pathology Unit, University and Hospital Trust of Verona, Verona, Italy.
Iacovelli R; Medical Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Porta C; Chair of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy.
Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy.
Pokaż więcej
Źródło :
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2021 May 18; Vol. 13, pp. 17588359211019642. Date of Electronic Publication: 2021 May 18 (Print Publication: 2021).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapy.
Autorzy :
Sbrana A; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Antognoli R; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Pasqualetti G; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy. Electronic address: .
Linsalata G; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Okoye C; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Calsolaro V; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Paolieri F; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Bloise F; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Ricci S; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Antonuzzo A; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy. Electronic address: .
Monzani F; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Pokaż więcej
Źródło :
Journal of geriatric oncology [J Geriatr Oncol] 2020 Apr; Vol. 11 (3), pp. 503-507. Date of Electronic Publication: 2019 Oct 28.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/therapy
Immunotherapy*
Lung Neoplasms*
Aged ; Aged, 80 and over ; Female ; Geriatric Assessment ; Humans ; Male ; Prognosis
Czasopismo naukowe
Tytuł :
Dedifferentiated liposarcoma: when eribulin can make the difference.
Autorzy :
Sbrana A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Paolieri F; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Bloise F; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Manacorda S; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Nuzzo A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Sammarco E; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Galli L; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Falcone A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Pokaż więcej
Źródło :
Future oncology (London, England) [Future Oncol] 2020 Jan; Vol. 16 (1s), pp. 21-24. Date of Electronic Publication: 2019 Dec 24.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Furans/*therapeutic use
Ketones/*therapeutic use
Liposarcoma/*diagnosis
Liposarcoma/*drug therapy
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Disease Progression ; Fatal Outcome ; Furans/administration & dosage ; Furans/adverse effects ; Humans ; Ketones/administration & dosage ; Ketones/adverse effects ; Male ; Retreatment ; Tomography, X-Ray Computed ; Treatment Outcome
Czasopismo naukowe
Tytuł :
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.
Autorzy :
Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sbrana A; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Rofi E; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Paolieri F; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Gianfilippo G; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Galli L; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Falcone A; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Morganti R; Section of Statistics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Porta C; Department of Internal Medicine, University of Pavia, Pavia, Italy.; Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy.
Efstathiou E; Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
van Schaik R; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jenster G; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2019 May 04. Date of Electronic Publication: 2019 May 04.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies